eli lilly glp-1 drugs Novo, weight-loss should be first option obesity treatments, European doctors say What Eli Lilly's new obesity
Description
Healthcare providers must fully inform patients about the serious side effects, including the risk of developing gastroparesis
10.1007/s00125-015-3625-5
doi:10.1056/NEJMoa2301972 206
Schoretsanitis, G., Weiler, S., Barbui, C., Raschi, E
Drug names in the diabetes space are notoriously confusing
As a result of these findings, the collaborators suggested 'proglucagon 78-107 may be the incretin of the lower gut' (Holst, rskov, Vagn Nielsen, Schwartz)
